SEC Info - Vasavada Amit - ‘4’ for 7/12/22 re: Marrone Bio Innovations Inc.

<?xml version="1.0" encoding="windows-1252"?>

<issuerName> MARRONE BIO INNOVATIONS INC </issuerName>

</issuer>

<rptOwnerName> Vasavada Amit </rptOwnerName>

</reportingOwnerId>

<rptOwnerStreet1> C/O MARRONE BIO INNOVATIONS, INC. </rptOwnerStreet1>

<rptOwnerStreet2> 7780-420 BRIER CREEK PARKWAY </rptOwnerStreet2>

<rptOwnerCity> RALEIGH </rptOwnerCity>

</reportingOwnerAddress>

</reportingOwnerRelationship>

</reportingOwner>

<value> Common Stock </value>

</securityTitle>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</nonDerivativeTransaction>

<value> Common Stock </value>

</securityTitle>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</nonDerivativeTransaction>

</nonDerivativeTable>

<value> Restricted Stock Units </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy) </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

<value> Stock Option (Right to Buy </value>

</securityTitle>

</conversionOrExercisePrice>

</transactionDate>

</transactionCoding>

</transactionTimeliness>

</transactionShares>

</transactionPricePerShare>

</transactionAcquiredDisposedCode>

</transactionAmounts>

</exerciseDate>

</expirationDate>

<value> Common Stock </value>

</underlyingSecurityTitle>

</underlyingSecurityShares>

</underlyingSecurity>

</sharesOwnedFollowingTransaction>

</postTransactionAmounts>

</directOrIndirectOwnership>

</ownershipNature>

</derivativeTransaction>

</derivativeTable>

<footnote id="F1"> Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). </footnote>

<footnote id="F2"> The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. </footnote>

<footnote id="F3"> The number of securities reported also reflects the acquisition of a total of 37,878 shares of the issuer's common stock pursuant to the issuer's employee stock purchase plan. </footnote>

<footnote id="F4"> Disposed of pursuant to the Merger Agreement in exchange for 22,147 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger, and 3,012 restricted stock units (each restricted stock unit represents a contingent right to receive one Ordinary Share of BIOX). </footnote>

<footnote id="F5"> Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. </footnote>

<footnote id="F6"> Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. </footnote>

<footnote id="F7"> This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was assumed by BIOX with respect to 105,596 shares and replaced with an option to purchase 7,027 Ordinary Shares of BIOX for $7.16 per share. The remainder of the option was cancelled in the Merger in exchange for 4,018 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. </footnote>

<footnote id="F8"> This option, which provided for vesting with respect to 1/4 of the total shares subject to the option on the first anniversary of the vesting commencement date of April 4, 2016, and with respect to 1/48 of the total shares subject to the option monthly thereafter for 36 months, was cancelled in the Merger in exchange for 285 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. </footnote>

<footnote id="F9"> This option, which provided for vesting 1/3 of the total shares subject to the option on the first anniversary of the vesting commencement date of March 1, 2016, and with respect to 1/36 of the total shares subject to the option monthly thereafter for 24 months, was assumed by BIOX in the Merger and replaced with an option to purchase 4,400 Ordinary Shares of BIOX for $13.98 per share. </footnote>

<footnote id="F10"> This option, which provided for vesting over a period of four years, vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 17,600 Ordinary Shares of BIOX for $16.36 per share. </footnote>

<footnote id="F11"> This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 22,000 Ordinary Shares of BIOX for $18.75 per share. </footnote>

<footnote id="F12"> This option, which provided for vesting with respect to 100% of the total shares subject to the option on December 31, 2015, was assumed by BIOX in the Merger and replaced with an option to purchase 1,056 Ordinary Shares of BIOX for $32.61 per share. </footnote>

<footnote id="F13"> This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of March 24, 2014, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 3,520 Ordinary Shares of BIOX for $166.93 per share. </footnote>

</footnotes>

<signatureName> /s/ Linda V. Moore, as attorney in fact </signatureName>

</ownerSignature>

</ownershipDocument>

Vasavada Amit – ‘4’ for 7/12/22 re: Marrone Bio Innovations Inc.

On: Friday, 7/15/22, at 11:15am ET · For: 7/12/22 · As: Officer · Accession #: 1209191-22-42223 · File #: 1-36030

Previous ‘4’: ‘4/A’ on 3/18/22 for 2/7/22 · Latest ‘4’: This Filing

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34

Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Vasavada Amit – ‘4’ for 7/12/22 re: Marrone Bio Innovations Inc.

On: Friday, 7/15/22, at 11:15am ET · For: 7/12/22 · As: Officer · Accession #: 1209191-22-42223 · File #: 1-36030

Previous ‘4’: ‘4/A’ on 3/18/22 for 2/7/22 · Latest ‘4’: This Filing

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34

Filing Table of Contents